(RTTNews) - While reporting financial results for the fourth quarter on Monday, pet healthcare provider IDEXX Laboratories, Inc. (IDXX) initiated its earnings and revenue guidance for the full-year 2026, in line with analysts' estimates.
For fiscal 2026, the company now projects earnings in a range of $14.29 to $14.80 per share on revenues between $4.632 billion and $4.720 billion, with revenue growth of 7.6 to 9.6 percent and organic revenue growth of 7 to 9 percent.
On average, analysts polled expect the company to report earnings of $14.45 per share on revenues of $4.66 billion for the year. Analysts' estimates typically exclude special items. In Monday's pre-market trading, IDXX is trading on the Nasdaq at $669.95, down $0.51 or 0.08 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
